

Multiple Myeloma Market - 2024-2032

<https://marketpublishers.com/r/MF951E9D497BEN.html>

Date: January 2026

Pages: 207

Price: US\$ 2,999.00 (Single User License)

ID: MF951E9D497BEN

Abstracts

The Multiple Myeloma Market was valued at US\$ 22.3 billion in 2024 and is anticipated to reach US\$ 34.58 billion by 2032, at a CAGR of 0.056 from 2026 to 2032.

The report delivers in-depth insights into key market dynamics, including regional growth trends, market segmentation, CAGR projections, and the revenue performance of leading industry players. It also highlights major growth drivers shaping the market landscape. Designed to provide a clear and comprehensive perspective, the report offers a detailed view of the current market size in terms of both value and volume, along with emerging opportunities and the overall development outlook of the Multiple Myeloma Market.

This report delivers a comprehensive overview of the Multiple Myeloma Market, with both quantitative and qualitative analyses, to help readers develop growth strategies, assess the competitive landscape, evaluate their position in the current market, and make informed business decisions regarding Multiple Myeloma Market. The Multiple Myeloma Market size, estimates, and forecasts are provided in terms of output/shipments (K MT) and revenue (US\$ millions), with 2025 as the base year and historical and forecast data for 2024–2032.

Multiple Myeloma Market Scope:

By Type

Smoldering (Indolent) Multiple Myeloma

Active (Symptomatic) Multiple Myeloma

By Treatment

Chemotherapy

Immunotherapy

Radiation

Stem Cell Transplant

Targeted Therapy

By End-User

Hospitals

Cancer Centers

Others

Key Players

Key Market Players

Amgen Inc.

Sanofi

Novartis AG

Teva Pharmaceutical Industries Ltd.

Johnson & Johnson Services, Inc.

Bristol-Myers Squibb Company

ONO PHARMACEUTICAL CO., LTD.

Pfizer Inc.

Karyopharm

Amneal Pharmaceuticals LLC. Similar data will be provided for each market player. Emerging Market Players

GSK plc

Takeda Pharmaceutical Company Limited

Poseida Therapeutics

Regeneron Pharmaceuticals, Inc.

Genentech, Inc. Similar data will be provided for each market player.

Major Highlights

This report delivers a comprehensive overview of the Multiple Myeloma Market, with both quantitative and qualitative analyses, to help readers develop growth strategies, assess the competitive landscape, evaluate their position in the current market, and make informed business decisions regarding Multiple Myeloma Market. The Multiple Myeloma Market size, estimates, and forecasts are provided in terms of output/shipments (K Sqm) and revenue (US\$ millions), with 2025 as the base year and historical and forecast data for 2024–2032.

This report will assist keyword manufacturers, new entrants, and companies across the industry value chain with information on revenues, production, and average prices for the overall market and its sub-segments, by company, by Type, by Application, and by region.

Regional Analysis:

North America (U.S., Canada, Mexico)

Europe (U.K., Italy, Germany, Russia, France, Spain, The Netherlands and Rest

of Europe)

Asia-Pacific (India, Japan, China, South Korea, Australia, Indonesia Rest of Asia Pacific)

South America (Colombia, Brazil, Argentina, Rest of South America)

Middle East & Africa (Saudi Arabia, U.A.E., South Africa, Rest of Middle East & Africa)

Partner Identification

Increase Your Customer Base by 3X using our Partner Identification tool

Uncover strategic collaboration opportunities with DataM vetted partners aligned to your ecosystem.

Identify high potential M&A targets based on synergies, market positioning and growth trajectory.

Prioritize partners by strategic fit rather than general capability.

Why Choose DataM?

Data-Driven Insights: Dive into detailed analyses with granular insights such as pricing, market shares and value chain evaluations, enriched by interviews with industry leaders and disruptors.

Post-Purchase Support and Expert Analyst Consultations: As a valued client, gain direct access to our expert analysts for personalized advice and strategic guidance, tailored to your specific needs and challenges.

White Papers and Case Studies: Benefit quarterly from our in-depth studies related to your purchased titles, tailored to refine your operational and marketing strategies for maximum impact.

Annual Updates on Purchased Reports: As an existing customer, enjoy the

privilege of annual updates to your reports, ensuring you stay abreast of the latest market insights and technological advancements. Terms and conditions apply.

Specialized Focus on Emerging Markets: DataM differentiates itself by delivering in-depth, specialized insights specifically for emerging markets, rather than offering generalized geographic overviews. This approach equips our clients with a nuanced understanding and actionable intelligence that are essential for navigating and succeeding in high-growth regions.

Value of DataM Reports: Our reports offer specialized insights tailored to the latest trends and specific business inquiries. This personalized approach provides a deeper, strategic perspective, ensuring you receive the precise information necessary to make informed decisions. These insights complement and go beyond what is typically available in generic databases.

Target Audience 2026

Manufacturers/ Buyers

Industry Investors/Investment Bankers

Research Professionals

Emerging Companies

Contents

1. METHODOLOGY AND SCOPE

- 1.1. Research Methodology
- 1.2. Research Objective and Scope of the Report

2. DEFINITION AND OVERVIEW

3. EXECUTIVE SUMMARY

- 3.1. Snippet by Type
- 3.2. Snippet by Treatment
- 3.3. Snippet by End-User
- 3.4. Snippet by Region

4. DYNAMICS

- 4.1. Impacting Factors
 - 4.1.1. Drivers
 - 4.1.1.1. Rising number of product approvals
 - 4.1.2. Restraints
 - 4.1.2.1. High costs of treatment
 - 4.1.3. Opportunity
 - 4.1.4. Impact Analysis

5. INDUSTRY ANALYSIS

- 5.1. Porter's Five Force Analysis
- 5.2. Supply Chain Analysis
- 5.3. Pricing Analysis
- 5.4. Patent Analysis
- 5.5. Regulatory Analysis
- 5.6. SWOT Analysis
- 5.7. Unmet Needs

6. BY TYPE

- 6.1. Introduction

- 6.1.1. Analysis and Y-o-Y Growth Analysis (%), By Type
- 6.1.2. Market Attractiveness Index, By Type
- 6.2. Smoldering (Indolent) Multiple Myeloma*
 - 6.2.1. Introduction
 - 6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
- 6.3. Active (Symptomatic) Multiple Myeloma

7. BY TREATMENT

- 7.1. Introduction
 - 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
 - 7.1.2. Market Attractiveness Index, By Treatment
- 7.2. Chemotherapy*
 - 7.2.1. Introduction
 - 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
- 7.3. Immunotherapy
- 7.4. Radiation
- 7.5. Stem Cell Transplant
- 7.6. Targeted Therapy

8. BY END-USER

- 8.1. Introduction
 - 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
 - 8.1.2. Market Attractiveness Index, By End-User
- 8.2. Hospitals*
 - 8.2.1. Introduction
 - 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
- 8.3. Cancer Centers
- 8.4. Others

9. BY REGION

- 9.1. Introduction
 - 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
 - 9.1.2. Market Attractiveness Index, By Region
- 9.2. North America
 - 9.2.1. Introduction
 - 9.2.2. Key Region-Specific Dynamics

- 9.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
- 9.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
- 9.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
- 9.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
 - 9.2.6.1. U.S.
 - 9.2.6.2. Canada
 - 9.2.6.3. Mexico

9.3. Europe

- 9.3.1. Introduction
- 9.3.2. Key Region-Specific Dynamics
- 9.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
- 9.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
- 9.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
- 9.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
 - 9.3.6.1. Germany
 - 9.3.6.2. U.K.
 - 9.3.6.3. France
 - 9.3.6.4. Spain
 - 9.3.6.5. Italy
 - 9.3.6.6. Rest of Europe

9.4. South America

- 9.4.1. Introduction
- 9.4.2. Key Region-Specific Dynamics
- 9.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
- 9.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
- 9.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
- 9.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
 - 9.4.6.1. Brazil
 - 9.4.6.2. Argentina
 - 9.4.6.3. Rest of South America

9.5. Asia-Pacific

- 9.5.1. Introduction
- 9.5.2. Key Region-Specific Dynamics
- 9.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
- 9.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
- 9.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
- 9.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
 - 9.5.6.1. China
 - 9.5.6.2. India

9.5.6.3. Japan

9.5.6.4. South Korea

9.5.6.5. Rest of Asia-Pacific

9.6. Middle East and Africa

9.6.1. Introduction

9.6.2. Key Region-Specific Dynamics

9.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type

9.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment

9.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User

10. COMPETITIVE LANDSCAPE

10.1. Competitive Scenario

10.2. Market Positioning/Share Analysis

10.3. Mergers and Acquisitions Analysis

11. COMPANY PROFILES

11.1. Key Market Players

11.2. Amgen Inc.*

11.2.1. Company Overview

11.2.2. Product Portfolio

11.2.2.1. Product Description

11.2.2.2. Product Key Performance Indicators (KPIs)

11.2.2.3. Historic and Forecasted Product Sales

11.2.2.4. Product Sales Volume

11.2.3. Financial Overview

11.2.3.1. Company Revenue's

11.2.3.2. Geographical Revenue Shares

11.2.3.3. Revenue Forecasts

11.2.4. Key Developments

11.2.4.1. Mergers & Acquisitions

11.2.4.2. Key Product Development Activities

11.2.4.3. Regulatory Approvals etc.

11.2.5. SWOT Analysis

11.3. Sanofi

11.4. Novartis AG

11.5. Teva Pharmaceutical Industries Ltd.

11.6. Johnson & Johnson Services, Inc.

- 11.7. Bristol-Myers Squibb Company
- 11.8. ONO PHARMACEUTICAL CO., LTD.
- 11.9. Pfizer Inc.
- 11.10. Karyopharm
- 11.11. Amneal Pharmaceuticals LLC. Similar data will be provided for each market player. Emerging Market Players
- 11.12. GSK plc*
 - 11.12.1. Pipeline Products Description
 - 11.12.2. Product Key Performance Indicators (KPIs)
 - 11.12.3. Key Activities
 - 11.12.4. Market Entry Timelines
 - 11.12.5. Product Penetration Rate
 - 11.12.6. Sales Estimation and Projections
- 11.13. Takeda Pharmaceutical Company Limited
- 11.14. Poseida Therapeutics
- 11.15. Regeneron Pharmaceuticals, Inc.
- 11.16. Genentech, Inc. Similar data will be provided for each market player. (*LIST NOT EXHAUSTIVE)

12. APPENDIX

- 12.1. About Us and Services
- 12.2. Contact Us

I would like to order

Product name: Multiple Myeloma Market - 2024-2032

Product link: <https://marketpublishers.com/r/MF951E9D497BEN.html>

Price: US\$ 2,999.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/MF951E9D497BEN.html>